title: Clinical and angiographic follow-up in patients with Cypher or Taxus stents in populations with high percentage of trial-excluded lesions.
abstract: BACKGROUND
  Drug-eluting stents (DESs) are being used in real life in patients with complex lesions usually excluded from the published trials. It is reasonable to think that the results could be worse, and the performance may be different between DES when these complex lesions are included.
  
  
  METHODS
  To investigate this issue, we studied our first 82 patients with DES (54 patients with Cypher (C) and 28 patients with Taxus (T) (129 lesions, with 1.57 lesions per patient). Seventy-one complex lesions were treated with C stent, 41 with T stent, and 17 with no DES. It was a high-risk population, as reflected by 64% unstable angina and 40% diabetes mellitus. Of the 112 DES complex lesions treated, 38% would have been excluded from the Sirius and Taxus IV trials.
  
  
  RESULTS
  The main data on intra-segment angiographic measures showed a late luminal loss lower for the C stent than for the T stent (0.17+/-0.45 and 0.44+/-0.6, P=.02, respectively). The restenosis and target lesion revascularization percentages were also lower for the C stent (8.4% vs. 24.4%, P=.07 and 5.6% vs. 17.1%, P<.05, respectively). In the complex lesions without restenosis, 28% would have been excluded from the trials, while in complex lesions with restenosis, there were 53% (P=.05) (with a homogeneous percentage between the C and T groups). The predictor variables of restenosis in the 112 DES-treated complex lesions were length (P=.03, IC=0.97-1.6) and the pre-reference diameter (P=.06).
  
  
  CONCLUSIONS
  In our experience, the C stent is superior to the T stent when treating populations with a high percentage of complex lesions excluded from the trials.
authors.affiliation: Interventional Cardiology Section, Cardiology Service, Infanta Cristina Hospital, Extremadura University, Badajoz, Spain. jrlminguez@hotmail.com
authors.forename: José R
authors.initials: JR
authors.lastname: López-Mínguez
authors.forename: Juan M
authors.initials: JM
authors.lastname: Nogales
authors.forename: Angel
authors.initials: A
authors.lastname: Morales
authors.forename: Rafael
authors.initials: R
authors.lastname: Alonso
authors.forename: Reyes
authors.initials: R
authors.lastname: González
authors.forename: Antonio
authors.initials: A
authors.lastname: Merchán
mesh_terms: D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging* / Q000209:etiology; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D012107:Research Design; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible